A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26weeks prior to the first administration of study intervention

• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) atscreening and baseline

• Total psoriasis area and severity index (PASI) >=12 at screening and baseline

• Total investigator global assessment (IGA) >=3 at screening and baseline

• Candidate for phototherapy or systemic treatment for plaque psoriasis

• A female participant of childbearing potential must have a negative highly sensitiveserum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and anegative urine pregnancy test at Week 0 prior to administration of studyintervention

Exclusion Criteria:

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)

• Current drug-induced psoriasis (for example, a new onset of psoriasis or anexacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolledrenal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,hematologic, rheumatologic, psychiatric, or metabolic disturbances

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients

• Major surgical procedures, (for example, requiring general anesthesia) within 8weeks before screening, or will not have fully recovered from a surgical procedureor has a surgical procedure planned during the time the participant is expected toparticipate in the study